PUBLISHED 11 September 2023 First head-to-head trial of biologics in EGPA, comparing a single monthly injection of Fasenra to three injections per month of mepolizumab Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s Fasenra (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared…...
US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica
The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients. Kevzara has been approved as the first and only biologic indicated for PMR adult patients who did not respond to corticosteroids or who cannot tolerate corticosteroid taper. Developed using…...